Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis

International Journal of Antimicrobial Agents

Volumn 49, Issue 6, 2017, Pages 688-694

  Kamp, Jasper ^a   Bolhuis, Mathieu S ^a   Tiberi, Simon ^b,c   Akkerman, Onno W ^a   Centis, Rosella ^d   de Lange, Wiel C ^a   Kosterink, Jos G ^a,e   van der Werf, Tjip S ^a   Migliori, Giovanni B ^d   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c E Morelli Hospital   (Italy)

^d IRCCS   (Italy)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Linezolid; Multi drug resistance; Population pharmacokinetics; TDM; Tuberculosis

Indexed keywords

LINEZOLID; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG MONITORING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PHARMACOKINETIC PARAMETERS; POPULATION PHARMACOKINETIC MODEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VALIDATION PROCESS; VOLUME OF DISTRIBUTION; AGED; BLOOD ANALYSIS; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BLOOD CHEMICAL ANALYSIS; FEMALE; HUMANS; ITALY; LINEZOLID; MALE; MIDDLE AGED; MODELS, STATISTICAL; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 85017463498     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.01.017     Document Type: Article

References (30)

1. World Health Organization, Towards tuberculosis elimination: an action framework for low-incidence countries. 2014, WHO, Geneva.
2. World Health Organization, Global tuberculosis report. 2016, WHO, Geneva.
3. Garcia-Prats, A.J., Rose, P.C., Hesseling, A.C., Schaaf, H.S., Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb) 94 (2014), 93–104.
4. Migliori, G.B., Sotgiu, G., Gandhi, N.R., Falzon, D., DeRiemer, K., Centis, R., et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 42 (2013), 169–179.
5. Falzon, D., Gandhi, N., Migliori, G.B., Sotgiu, G., Cox, H.S., Holtz, T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 42 (2013), 156–168.
6. Tiberi, S., D'Ambrosio, L., De Lorenzo, S., Viggiani, P., Centis, R.M.M.G., Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. Eur Respir J 47 (2009), 664–667.
7. Tasneen, R., Betoudji, F., Tyagi, S., Li, S.-Y., Williams, K., Converse, P.J., et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother 60 (2015), 270–277.
8. Guglielmetti, L., Le Dû, D., Jachym, M., Henry, B., Martin, D., Caumes, E., et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 60 (2015), 188–194.
9. Zou, L., Liu, M., Wang, Y., Lu, J., Pang, Y., Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates. Tuberculosis (Edinb) 95 (2015), 839–842.
10. Weiss, T., Schonfeld, N., Otto-Knapp, R., Bos, L., Bettermann, G., Mauch, H., et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J 45 (2015), 285–287.
11. Zhang, M., Sala, C., Dhar, N., Vocat, A., Sambandamurthy, V.K., Sharma, S., et al. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 58 (2014), 3217–3223.
12. Migliori, G.B., Eker, B., Richardson, M.D., Sotgiu, G., Zellweger, J.-P., Skrahina, A., et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 34 (2009), 387–393.
13. Lee, M., Cho, S.N., Barry, C.E. 3rd, Song, T., Kim, Y.J.I., Linezolid for XDR-TB—final study outcomes. N Engl J Med 373 (2015), 290–291.
14. Bolhuis, M.S., Tiberi, S., Sotgiu, G., De Lorenzo, S., Kosterink, J.G.W., van der Werf, T.S., et al. Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. Eur Respir J 46 (2015), 1205–1207.
15. Tang, S., Yao, L., Hao, X., Zhang, X., Liu, G., Liu, X., et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 45 (2014), 1–10.
16. Koh, W.-J., Kang, Y.R., Jeon, K., Kwon, O.J., Lyu, J., Kim, W.S., et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 67 (2012), 1503–1507.
17. Alsultan, A., Peloquin, C., Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74 (2014), 839–854.
18. Ashkin, D., Houpt, E.R., Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in Virginia, 2009–2014. Tuberc Respir Dis (Seoul) 78 (2015), 78–84.
19. Alffenaar, J.-W.C., Kosterink, J.G.W., van Altena, R., van der Werf, T.S., Uges, D.R., Proost, J.H., Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 32 (2010), 97–101.
20. Andes, D., van Ogtrop, M.L., Peng, J., Craig, W.A., In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 46 (2002), 3484–3489.
21. Boak, L.M., Li, J., Rayner, C.R., Nation, R.L., Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother 51 (2007), 1287–1292.
22. Rayner, C.R., Forrest, A., Meagher, A.K., Birmingham, M.C., Schentag, J.J., Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42 (2003), 1411–1423.
23. Dietze, R., Hadad, D.J., McGee, B., Molino, L.P.D., Maciel, E.L.N., Peloquin, C.A., et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 178 (2008), 1180–1185.
24. Harmelink, I.M., Alffenaar, J.W.C., Wessels, M.A., Greijdanus, B., Uges, D.R., Rapid and sensitive liquid chromatography—tandem mass spectrometry method for the determination of linezolid in human serum. J Chromatogr B 877 (2009), 3194–3200.
25. Schön, T., Juréen, P., Chryssanthou, E., Giske, C.G., Sturegård, E., Kahlmeter, G., et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 15 (2011), 502–509.
26. Bolhuis, M.S., van Altena, R., Uges, D.R., van der Werf, T.S., Kosterink, J.G.W., Alffenaar, J.-W.C., Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 54 (2010), 5418–5419.
27. Plock, N., Buerger, C., Joukhadar, C., Kljucar, S., Kloft, C., Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos 35 (2007), 1816–1823.
28. Meagher, A.K., Forrest, A., Rayner, C.R., Birmingham, M.C., Schentag, J.J., Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 47 (2003), 548–553.
29. Zhang, X., Falagas, M.E., Vardakas, K.Z., Wang, R., Qin, R., Wang, J., et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 7 (2015), 603–615.
30. Sotgiu, G., Centis, R., D'Ambrosio, L., Alffenaar, J.-W.C., Anger, H.A., Caminero, J.A., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 40 (2012), 1430–1442.